Company Filing History:
Years Active: 2010-2013
Title: Claudie Madoulet: Innovator in Cancer Treatment
Introduction
Claudie Madoulet is a prominent inventor based in Reims, France. She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic vaccines. With a total of 2 patents, her work focuses on addressing multidrug resistance in cancer therapies.
Latest Patents
Madoulet's latest patents include a therapeutic vaccine targeted against P-glycoprotein 170. This vaccine aims to inhibit multidrug resistance in the treatment of cancers. The invention involves an immunogenic composition that comprises a carrier and an antigenic structure. This structure includes conjugates made from amino acid sequences of peptides derived from an extracellular loop of the P-170 protein. Each peptide is combined with several fatty acid molecules containing carbon chains between C12 and C24. This combination allows for the induction of anti-P-170 antibodies under suitable administration conditions. The composition is designed to provide means for treating multidrug resistances effectively.
Career Highlights
Claudie Madoulet is currently associated with Ac Immune SA, where she continues her groundbreaking work in immunotherapy. Her research has the potential to transform cancer treatment and improve patient outcomes significantly.
Collaborations
Some of her notable coworkers include Pierre-Francois Tosi and Claude Nicolau. Their collaboration enhances the innovative efforts in the field of cancer research.
Conclusion
Claudie Madoulet's contributions to cancer treatment through her innovative patents highlight her role as a leading inventor in the medical field. Her work continues to inspire advancements in therapeutic approaches to combat multidrug resistance in cancer therapies.